X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1232) 1232
Publication (105) 105
Book Review (20) 20
Newsletter (11) 11
Newspaper Article (7) 7
Magazine Article (3) 3
Book Chapter (1) 1
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (979) 979
index medicus (634) 634
oncology (619) 619
fluorouracil (599) 599
female (577) 577
chemotherapy (554) 554
male (438) 438
middle aged (427) 427
aged (409) 409
antineoplastic combined chemotherapy protocols - therapeutic use (402) 402
cancer (396) 396
fluorouracil - administration & dosage (394) 394
colorectal cancer (320) 320
adult (308) 308
colorectal neoplasms - drug therapy (299) 299
treatment outcome (253) 253
fluorouracil - therapeutic use (248) 248
leucovorin (228) 228
cost-benefit analysis (216) 216
oxaliplatin (216) 216
5-fluorouracil (205) 205
capecitabine (192) 192
care and treatment (190) 190
therapy (185) 185
antineoplastic combined chemotherapy protocols - economics (184) 184
deoxycytidine - analogs & derivatives (171) 171
fluorouracil - economics (164) 164
aged, 80 and over (163) 163
survival (162) 162
antineoplastic agents - therapeutic use (158) 158
colorectal neoplasms - pathology (156) 156
medicine & public health (154) 154
pharmacology & pharmacy (152) 152
metastasis (146) 146
research (146) 146
analysis (144) 144
fluorouracil - adverse effects (144) 144
breast neoplasms - drug therapy (142) 142
fluorouracil - analogs & derivatives (142) 142
antineoplastic combined chemotherapy protocols - adverse effects (141) 141
surgery (134) 134
leucovorin - administration & dosage (133) 133
1st-line treatment (130) 130
neoplasm staging (130) 130
retrospective studies (128) 128
antineoplastic combined chemotherapy protocols - administration & dosage (126) 126
bevacizumab (126) 126
trial (126) 126
survival analysis (123) 123
disease-free survival (122) 122
irinotecan (120) 120
quality of life (119) 119
neoplasm metastasis (118) 118
breast cancer (115) 115
drug therapy (108) 108
chemotherapy, adjuvant (105) 105
cancer therapies (103) 103
health aspects (103) 103
carcinoma (102) 102
colorectal neoplasms - economics (101) 101
antimetabolites, antineoplastic - therapeutic use (99) 99
deoxycytidine - administration & dosage (98) 98
prognosis (98) 98
camptothecin - analogs & derivatives (96) 96
cost-effectiveness (92) 92
organoplatinum compounds - administration & dosage (92) 92
adjuvant treatment (91) 91
animals (91) 91
colonic neoplasms - drug therapy (90) 90
patients (90) 90
colon cancer (89) 89
colorectal-cancer (88) 88
adjuvant chemotherapy (87) 87
survival rate (87) 87
health care sciences & services (86) 86
randomized-trial (83) 83
cisplatin (82) 82
prospective studies (82) 82
antimetabolites, antineoplastic - administration & dosage (80) 80
randomized controlled trials as topic (80) 80
antineoplastic agents - economics (73) 73
cetuximab (73) 73
deoxycytidine - therapeutic use (73) 73
drug administration schedule (73) 73
leucovorin - economics (71) 71
clinical trials (70) 70
leucovorin - therapeutic use (70) 70
colorectal neoplasms - mortality (67) 67
colon-cancer (66) 66
follow-up studies (66) 66
radiotherapy (66) 66
toxicity (66) 66
deoxycytidine - economics (65) 65
quality-adjusted life years (65) 65
antineoplastic agents - administration & dosage (64) 64
hematology, oncology and palliative medicine (64) 64
metastatic colorectal-cancer (64) 64
risk factors (64) 64
gastroenterology & hepatology (63) 63
phase-iii (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1221) 1221
French (9) 9
German (5) 5
Japanese (4) 4
Chinese (3) 3
Russian (3) 3
Spanish (3) 3
Czech (2) 2
Danish (2) 2
Dutch (2) 2
Portuguese (2) 2
Arabic (1) 1
Italian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 3, pp. 516 - 522
Abstract Background Limited data exist on the economic consequences of implementing targeted therapy (TT) for metastatic renal cell carcinoma (RCC) in a... 
Urology | Metastatic renal cell carcinoma | Economic analysis | Population-based | Observational | National | Targeted therapy | Cost analysis | Implementation | 1ST-LINE TREATMENT | COST-EFFECTIVENESS | FINLAND | EVEROLIMUS | SUNITINIB MALATE | CANCER | INTERFERON-ALPHA | IMMUNOTHERAPY | 2ND-LINE TREATMENT | UROLOGY & NEPHROLOGY | Bevacizumab - therapeutic use | Everolimus - economics | Radiotherapy - economics | Humans | Middle Aged | Niacinamide - economics | Male | Antineoplastic Agents - therapeutic use | Efficiency | Employment - economics | Aged, 80 and over | Sirolimus - economics | Indoles - economics | Bevacizumab - economics | Costs and Cost Analysis | Protein Kinase Inhibitors - economics | Niacinamide - therapeutic use | Antineoplastic Agents - economics | Carcinoma, Renal Cell - economics | Indoles - therapeutic use | Ambulatory Care - economics | Phenylurea Compounds - economics | Drug Costs | Niacinamide - analogs & derivatives | Fluorouracil - economics | Interleukin-2 - economics | Interleukin-2 - therapeutic use | Immunologic Factors - economics | Fluorouracil - therapeutic use | Neoplasm Metastasis - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Angiogenesis Inhibitors - economics | Everolimus - therapeutic use | Female | Registries | Pyrroles - economics | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Radiography - economics | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - economics | Health Care Costs | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Denmark | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Hospitalization - economics | Immunologic Factors - therapeutic use | Economic aspects | Metastasis | Carcinoma, Renal cell
Journal Article
PharmacoEconomics, ISSN 1170-7690, 10/2018, Volume 36, Issue 10, pp. 1153 - 1163
As part of the single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited Celgene Ltd to submit clinical... 
Quality of Life Research | Health Economics | Health Administration | Public Health | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | PHASE-III TRIAL | PLUS GEMCITABINE | CAPECITABINE | SURVIVAL | CISPLATIN | HEALTH CARE SCIENCES & SERVICES | PHARMACOLOGY & PHARMACY | HEALTH POLICY & SERVICES | ECONOMICS | COMBINATION | Oxaliplatin - economics | Humans | Fluorouracil - economics | Oxaliplatin - therapeutic use | Models, Economic | Irinotecan - therapeutic use | Leucovorin - economics | Pancreatic Neoplasms - drug therapy | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Pancreatic Neoplasms - secondary | Nanoparticles - therapeutic use | Pancreatic Neoplasms - economics | Technology Assessment, Biomedical - statistics & numerical data | Antineoplastic Combined Chemotherapy Protocols - economics | Leucovorin - therapeutic use | Antineoplastic Agents, Phytogenic - therapeutic use | Capecitabine - economics | Paclitaxel - economics | Irinotecan - economics | Antimetabolites, Antineoplastic - economics | Capecitabine - therapeutic use | Cost-Benefit Analysis - statistics & numerical data | Deoxycytidine - economics | Paclitaxel - therapeutic use | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Nanoparticles - economics | Antineoplastic Agents, Phytogenic - economics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Deoxycytidine - analogs & derivatives | Nanoparticles | Clinical trials | Metastasis | Cost analysis | Patients | Pancreatic cancer | Review
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 07/2011, Volume 11, Issue 1, pp. 288 - 288
Background: XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown similar improvements in survival in patients with... 
CLINICAL-EXCELLENCE | UNITED-KINGDOM | ONCOLOGY | ACID PLUS OXALIPLATIN | OUTCOMES RESEARCH | RANDOMIZED PHASE-III | DRUGS | NICE | NATIONAL-INSTITUTE | HEALTH-CARE | PHARMACOECONOMICS | Drug Costs | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hong Kong | Length of Stay - economics | Humans | Middle Aged | Fluorouracil - economics | Male | Leucovorin - economics | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - economics | Female | Insurance, Health, Reimbursement - economics | Decision Making | Costs and Cost Analysis | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Deoxycytidine - economics | Adenocarcinoma - drug therapy | Colorectal Neoplasms - economics | Travel - economics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cost-Benefit Analysis | Health Care Costs - statistics & numerical data | Office Visits - economics | Organoplatinum Compounds - economics | Aged | Adenocarcinoma - economics | Deoxycytidine - analogs & derivatives | Hospitalization - economics | Decision-making | Chemotherapy | Care and treatment | Analysis | Colorectal cancer | Prospective payment systems (Medical care) | Research | Health aspects | Cancer
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2009, Volume 101, Issue 20, pp. 1412 - 1422
Background Although colorectal cancer screening is cost-effective, it requires a considerable net investment by governments or insurance companies. If... 
UNITED-STATES | COLON-CANCER | COLONOSCOPY | MORTALITY | RANDOMIZED CONTROLLED TRIAL | 1ST-LINE TREATMENT | ONCOLOGY | LARGE BOWEL | SERVICES TASK-FORCE | LARGE-INTESTINE | FECAL-OCCULT-BLOOD | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | United States | Humans | Middle Aged | Fluorouracil - economics | Male | Antineoplastic Agents - therapeutic use | Mass Screening - methods | Colorectal Neoplasms - diagnosis | Leucovorin - economics | Incidence | Camptothecin - economics | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Sigmoidoscopy - economics | Colorectal Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - economics | Colonoscopy - economics | Camptothecin - administration & dosage | Female | Occult Blood | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | SEER Program | Mass Screening - economics | Cost Savings - trends | Colorectal Neoplasms - prevention & control | Survival Rate | Antineoplastic Agents - economics | Colorectal Neoplasms - economics | Drug Costs - trends | Cost-Benefit Analysis | Selection Bias | Organoplatinum Compounds - economics | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Chemotherapy | Care and treatment | Control | Colorectal cancer | Diagnosis | Research | Health aspects | Medical care, Cost of | Cancer
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2013, Volume 137, Issue 1, pp. 187 - 193
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 4/2016, Volume 17, Issue 3, pp. 287 - 304
Background Actinic keratosis (AK) is a UV-induced, premalignant skin condition that is common in adults over 60 years of age with fair skin in Scotland. The... 
Economic analysis | Gels | Cryosurgery | Scalp | Dermatology | Comparators | Cream | Lesions | Cryotherapy | Cost efficiency | Health Economics | Economic Policy | Actinic keratosis | Public Health | Ingenol mebutate gel | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | ICER | Public Finance & Economics | Health Care Management | Cost-effectiveness | PHOTODYNAMIC THERAPY | CHEMOPREVENTION | SOLAR KERATOSES | TRIAL | 5-FLUOROURACIL | CREAM | 5-AMINOLEVULINIC ACID | UNCERTAINTY | HEALTH POLICY & SERVICES | ECONOMICS | SKIN-CANCER | Models, Econometric | Recurrence | Salicylic Acid - economics | Keratolytic Agents - economics | Humans | Fluorouracil - economics | Scotland | Diclofenac - economics | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Diterpenes - administration & dosage | Keratolytic Agents - administration & dosage | Quality-Adjusted Life Years | Cryotherapy - economics | Diclofenac - therapeutic use | Diterpenes - therapeutic use | Keratolytic Agents - therapeutic use | Keratolytic Agents - adverse effects | Treatment Outcome | Keratosis, Actinic - drug therapy | Salicylic Acid - therapeutic use | Cost-Benefit Analysis | Cryotherapy - methods | Diterpenes - economics | Diterpenes - adverse effects | Analysis | Skin | Studies | Economic models | Health economics | Economic theory | Skin diseases | Drug therapy | Willingness to pay
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 10/2012, Volume 13, Issue 5, pp. 589 - 603
Background In a phase III trial of women with HER2+ metastatic breast cancer (MBC) previously treated with trastuzumab, an anthracycline, and taxanes... 
Health care costs | Chemotherapy | Sensitivity analysis | Cost estimation models | Cost estimates | Utilities costs | Experimentation | Medications | Breast cancer | Cost efficiency | Economics | Cost and cost analysis | Economic Policy | Medicine & Public Health | Statistics for Life Sciences, Medicine, Health Sciences | Statistics for Business/Economics/Mathematical Finance/Insurance | Public Finance & Economics | Health Informatics | Breast neoplasms, secondary | Public Health/Gesundheitswesen | Lapatinib | Secondary | Breast neoplasms | SURVIVAL | UNITED-KINGDOM | CARE | TRIAL | GROWTH-FACTOR RECEPTOR | UNCERTAINTY | HEALTH POLICY & SERVICES | EXPERIENCE | PROGRESSION | Confidence Intervals | State Medicine | Women's Health | Breast Neoplasms - economics | Capecitabine | Humans | Fluorouracil - economics | Antineoplastic Agents - therapeutic use | Models, Economic | Antibodies, Monoclonal, Humanized - economics | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Female | Drug Therapy, Combination | Quality-Adjusted Life Years | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Probability | Antimetabolites, Antineoplastic - economics | United Kingdom | Deoxycytidine - economics | Breast Neoplasms - drug therapy | Antineoplastic Agents - economics | Antimetabolites, Antineoplastic - therapeutic use | Breast Neoplasms - psychology | Quinazolines - therapeutic use | Cost-Benefit Analysis | Quinazolines - economics | Deoxycytidine - analogs & derivatives | Trastuzumab | Studies | Economic models | Health care expenditures | Epidermal growth factor | Economic theory | Metastasis | Cost analysis | Economic statistics
Journal Article
Clinical Colorectal Cancer, ISSN 1533-0028, 2016, Volume 15, Issue 1, pp. 1 - 6
Abstract To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a... 
Hematology, Oncology and Palliative Medicine | Gastroenterology and Hepatology | Value | Chemotherapy | Incremental cost effectiveness ratio | Cost-effectiveness | Colorectal cancer | COST-EFFECTIVENESS ANALYSIS | UNITED-STATES | 2-STAGE HEPATECTOMY | PHASE-III | RANDOMIZED-TRIAL | GLUCURONOSYLTRANSFERASE 1A1 | BOLUS FLUOROURACIL | LIVER METASTASES | FLUOROURACIL DOSE ADJUSTMENT | ONCOLOGY | 1ST-LINE THERAPY | Drug Costs | United States | Humans | Fluorouracil - economics | Leucovorin - economics | Camptothecin - economics | Fluorouracil - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - economics | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - economics | Camptothecin - administration & dosage | Leucovorin - therapeutic use | Bevacizumab - economics | Camptothecin - analogs & derivatives | Quality-Adjusted Life Years | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Treatment Outcome | Cetuximab - economics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cost-Benefit Analysis | Cetuximab - administration & dosage | Organoplatinum Compounds - economics | Colorectal Neoplasms - pathology
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, p. e83396
Background: First-line postoperative adjuvant chemotherapies with S-1 and capecitabine and oxaliplatin (XELOX) were first recommended for resectable gastric... 
CAPECITABINE | TRIAL | THERAPY | MULTICENTER PHASE-II | ADENOCARCINOMA | GASTRECTOMY | MULTIDISCIPLINARY SCIENCES | OXALIPLATIN | ORAL FLUOROPYRIMIDINE | S-1 PLUS CISPLATIN | Markov Chains | Humans | Middle Aged | Fluorouracil - economics | Clinical Trials, Phase III as Topic | China | Antineoplastic Combined Chemotherapy Protocols - economics | Chemotherapy, Adjuvant - economics | Quality-Adjusted Life Years | Fluorouracil - analogs & derivatives | Oxonic Acid - economics | Probability | Models, Statistical | Stomach Neoplasms - drug therapy | Deoxycytidine - economics | Gastrectomy | Disease Progression | Disease-Free Survival | Cost-Benefit Analysis | Bayes Theorem | Stomach Neoplasms - economics | Tegafur - economics | Stomach Neoplasms - surgery | Deoxycytidine - analogs & derivatives | Drug Combinations | Cancer patients | Analysis | Adjuvant treatment | Economic aspects | Markov processes | Practice guidelines (Medicine) | Stomach cancer | Cancer | Health care | Clinical trials | Markov chains | Parameter sensitivity | Cancer therapies | Lymph nodes | Impact analysis | Gross Domestic Product--GDP | Chinese medicine | Utilities | Oxaliplatin | Surgery | Dissection | Gastric cancer | Pharmaceutical sciences | Sensitivity analysis | Patients | Chemotherapy | Hospitals | Pharmacy | Pharmacoeconomics | Economic impact | Cost analysis | Gross Domestic Product | GDP
Journal Article